News & Updates
Showing Multidisciplinary articles
Showing

ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?
ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.

Chiauranib extends PFS in platinum-resistant ovarian cancer, including in anti-angio–exposed patients
Chiauranib plus weekly paclitaxel significantly extends progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer, including those previously treated with anti-angiogenic agents, according to the findings of the phase III CHIPRO trial presented at ASCO 2026.

Direct-acting antivirals improve survival in patients with HCV-related HCC
A recent study in UK has shown a significant proportion of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) initiating direct-acting antiviral (DAA) therapy, resulting in improvements in sustained virological response (SVR) rates.






